Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Factor X Modulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Factor X, also known as Stuart-Prower factor, is a serine endopeptidase enzyme, which is synthesized in the liver and requires vitamin K for its synthesis, thus deficiency of both factor X and vitamin K results in hemolysis. Factor X inhibitors act as anticoagulants and competitively inhibit free and clot-bound factor Xa, which terminates the amplification of thrombin generation which is required to complete the clotting process. Factor X stimulants exert their action by binding to factor X and performing the required bridging activity for the launch of the coagulation cascade. Factor X inhibitors are indicated for the prevention of venous thromboembolic events, stroke, deep vein thrombosis, and pulmonary embolism. Factor X modulators are primarily used in the prevention of bleeding episodes. Daiichi Sankyo Pharmaceutical, Pfizer, Eisai, LEO Pharma, Roche, Astellas Pharma, AstraZeneca, Novartis, and Sanofi are some of the major players in the factor X modulators market.
Key Market Developments:
Approved Drug Molecules and Brand Names for Factor X Modulators:
Drugs under the Pipeline for Factor X Modulators:
Clinical Activity and Developments of Factor X Modulators:
Currently, there are about 39 drug products in the Factor X modulators, including 14 approved products in the market and others are in the clinical trial phases.
Molecule Name |
Number of Studies |
Darexaban maleate (YM150) |
26 |
Bevyxxa (Betrixaban) |
13 |
Ciraparantag (Aripazine) |
8 |
Abelacimab (MAA868) |
8 |
Idraparinux sodium (SANORG 34006) |
7 |
Otamixaban (XRP0673) |
6 |
MK-2060 |
5 |
ALT 836 |
3 |
Dimolegin (Dioxaban) |
3 |
IONIS-FXIRx |
3 |
Orgaran (Danaparoid) |
3 |
STSP-0601 |
3 |
Gruticibart (Ab023) |
2 |
Ckd-344 |
2 |
GCC-4401C |
2 |
REGN9933 |
2 |
Fesomersen (IONIS-FXI-LRx) |
1 |
Byclot (freeze-dried activated human blood coagulation factor VIIa concentrate containing factor X) |
1 |
RBD4059 |
1 |
REGN7508 |
1 |
SYHA136 |
1 |
Factor X inhibitors such as Rivaroxaban, Enoxaparin, Apixaban, Endoxaban, and others are indicated for deep vein thrombosis, embolism, pulmonary embolism, stroke, thromboembolism, thrombosis, venous thromboembolism. These drugs have also been registered for acute coronary syndromes and cardiovascular disorders, are in phase-III arterial thrombosis, peripheral arterial disorders, and venous thrombosis, and in phase-II for coronary thrombosis. Factor X stimulant like emicizumab is approved for the routine prophylaxis of bleeding episodes in patients with hemophilia A.
Download Free Sample Report
Rivaroxaban, Enoxaparin, Apixaban, Endoxaban, and Emicizumab are some of the approved Factor X modulators in the market.
Daiichi Sankyo Pharmaceutical, Pfizer, Eisai, LEO Pharma, Roche, Astellas Pharma, AstraZeneca, Novartis, and Sanofi are some of the major players in the factor X modulators market.
Major indications for Factor X modulators are prevention of venous thromboembolic events, stroke, deep vein thrombosis, and pulmonary embolism.
There are a total of 21 molecules in the clinical development phases for Factor X Modulators.
Key Market Players